Healthcare
Idorsia Ltd(IDRSF)
Live Price
Offline$7.50
+0.00% today
Window Change
+67.82%
Window
May 5, 2026 โ Jun 24, 2026
- Market Cap
- $790.00M
- Revenue Growth
- +96.5%
- EPS Growth
- +64.1%
- Dividend Yield
- 0.0%
Historical coverage is still filling in
This 1Y daily history view is currently sparse. Use it as directional context while we continue backfilling more history.
Coverage: 37 bars ยท May 5, 2026 โ Jun 24, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Idorsia Ltd (IDRSF) is a Healthcare stock with a market cap of $790.00M and listed on OTC. The stock last traded around $7.50 and up 67.8% across the available one-year price window (May 5, 2026 โ Jun 24, 2026). Baseline metrics include revenue growth of +96.5%, EPS growth of +64.1%, a dividend yield of 0.0%. What stands out right now is revenue +96.5%, EPS +64.1%, free cash flow +57.0% with operating margin -95.6% and ROIC -62.1%. Valuation is more restrained than many high-expectation growth names at price/sales 3.6. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines IDRSF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+96.5% vs +7.6% peer median
Operating Margin
Below sector median
-95.6% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on Apr 28, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +96.5% and EPS at +64.1%, with operating margin around -95.6%.
Benchmark Edge
IDRSF vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
IDRSF
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
IDRSF Max Drawdown
-6.67%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for IDRSF and SPY.
Company Overview
Idorsia Ltd
Other OTC
Idorsia Ltd, a biopharmaceutical company, discovers, develops, and commercializes drugs for unmet medical needs in Switzerland. The company has a clinical development pipeline that cover various therapeutic areas, including CNS, cardiovascular, and immunological disorders, as well as orphan diseases. Idorsia Ltd has a collaboration agreement with Janssen Biotech Inc. to jointly develop and commercialize aprocitentan and its derivative compounds or products; license agreement with Mochida Pharmaceutical for the supply, co-development, and comarketing of daridorexant; and Hoffman-La Roche Inc. to develop and market compounds in the field of cancer immunotherapy. It also has a collaboration with Antares Pharma, Inc. for the development of a self- administered drug device product for Selatogrel; and Neurocrine Biosciences, Inc. to develop and commercialize ACT-709478, which is in Phase II clinical trial for the treatment of epilepsy. The company was incorporated in 2017 and is headquartered in Allschwil, Switzerland.
- Leadership
- Jean-Paul Clozel
- IPO Date
- Jul 17, 2017
- Employees
- 1.1k
- Street Address
- Hegenheimermattweg 91
- Mailing
- Allschwil, 4123
- Region
- Allschwil, CH
- Reporting Currency
- USD
- Investor Line
- 41 58 844 10 10
- Last Updated
- Apr 30, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 3.6
- Price/Book
- โ
Growth
- Revenue
- +96.5%
- EPS
- +64.1%
- Free Cash Flow
- +57.0%
Profitability
- Gross Margin
- 87.9%
- Operating Margin
- -95.6%
- Net Margin
- -100.7%
- ROE
- 19.2%
- ROIC
- -62.1%
Balance Sheet
- Debt/Equity
- โ
- Current Ratio
- 1.60
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.